GlassScriptPhysician profile
Michael L Hadley
NPI 1699797811
$3,207.44
in general payments reported to CMS, 2019-2025
29 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $417 · 2021: $767 · 2022: $554 · 2023: $365 · 2024: $278 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,087.37 | 2019-2025 | |
| Allergan, INC. | $312.82 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $237.46 | 2020-2025 | |
| Galderma Laboratories, L.P. | $193.75 | 2019-2025 | |
| Genentech USA, INC. | $177.40 | 2019-2022 | |
| Ucb, INC. | $166.98 | 2021-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $121.33 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $121.27 | 2019-2025 | Libtayo |
| Sun Pharmaceutical Industries INC. | $101.36 | 2019-2023 | Absorica Ld, Winlevi, Ilumya |
| Amgen INC. | $82.71 | 2019-2024 | Otezla |
| Lilly USA, LLC | $70.98 | 2019-2025 | Ebglyss, Taltz |
| Genzyme Corporation | $55.41 | 2019-2021 | |
| Corcept Therapeutics | $50.48 | 2025 | Korlym |
| Leo Pharma INC. | $49.16 | 2022-2023 | Adbry |
| Biofrontera INC. | $48.27 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $43.09 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $39.00 | 2023-2024 | Spravato |
| Organon LLC | $37.04 | 2024-2025 | Vtama |
| Dermavant Sciences, INC. | $35.51 | 2023-2024 | Vtama |
| Incyte Corporation | $28.93 | 2025 | Opzelura |
| Mylan Pharmaceuticals INC. | $25.97 | 2019 | |
| Krystal Biotech INC | $21.31 | 2024 | Vyjuvek |
| Exact Sciences Corporation | $17.88 | 2025 | Cologuard Collection Kit |
| Dermira, INC. | $17.74 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $15.99 | 2019 | |
| Dusa Pharmaceuticals, INC. | $14.42 | 2019 | |
| Dynavax Technologies Corporation | $14.02 | 2024 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $13.77 | 2025 | Rexulti |
| Sensus Healthcare, INC. | $6.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hadley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.